Cite
HARVARD Citation
Ebata, S. et al. (2022). Percentage of residual B cells after 2 weeks of rituximab treatment predicts the improvement of systemic sclerosis‐associated interstitial lung disease. Journal of dermatology. 49 (1), pp. 179-183. [Online].